Updates are available Correction dated 2021-05-17
Click to view Correction: https://doi.org/10.1038/s41598-021-90075-z
-
Authors
Lidberg, Kevin A.
Annalora, Andrew J.
Jozic, Marija
Elson, Daniel J.
Wang, Lu
Bammler, Theo K.
Ramm, Susanne
Monteiro, Maria Beatriz
Himmelfarb, Jonathan
Marcus, Craig B.
Iversen, Patrick L.
Kelly, Edward J.
-
Funding
Funding for this research was provided by:
National Institutes of Health (ES007032 – 41A1, UH3TR000504)
- License Information
-
More Information
Article History
Received: 21 August 2020
Accepted: 10 February 2021
First Online: 25 February 2021
Change Date: 17 May 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41598-021-90075-z
Competing interests
: Dr. Annalora and Dr. Iversen share a U.S. patent with Oregon State University for RENAL SELECTIVE INHIBITION OF CYTOCHROME P450 3A5 (U.S. Patent No. 10,538,769), and seven patented PMO sequences targeting human CYP3A5 (shown in Table ) were utilized in this study. Author P.L. Iversen also has a financial interest in LS Pharma, LLC. Author’s Lidberg, Jozic, Elson, Wang, Bammler, Ramm, Monteiro, Kelly and Marcus have no financial conflicts of interest to report.
